Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04397679 · ClinicalTrials.gov registry record · Phase 1
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04397679 is a Phase 1 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT04397679, a Phase 1 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial studies the side effects of partial brain radiation therapy, temozolomide, chloroquine, and tumor treating fields therapy for the treatment of newly diagnosed glioblastoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chloroquine is normally used to treat strains of malaria and prior preclinical and clinical data suggests that it may increase the efficacy of both radiation and tumor treating fields therapy. Tumor treating fields therapy uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die. The purpose of this study is to determine the safety of partial brain radiation therapy, temozolomide, chloroquine, and tumor treating fields therapy in patients with gliobastoma
Interventions
- DRUG Temozolomide
- RADIATION Intensity-Modulated Radiation Therapy (IMRT)
- RADIATION 3-Dimensional Conformal Radiation Therapy
- DRUG Chloroquine
- PROCEDURE Tumor Treating Fields Therapy (TTF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2024-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04397679
The ClinicalTrials.gov registry entry for NCT04397679 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT04397679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04397679 about?
NCT04397679 is a clinical study titled "Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma". This trial studies the side effects of partial brain radiation therapy, temozolomide, chloroquine, and tumor treating fields therapy for the treatment of newly diagnosed glioblastoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozol...
What is the current status of trial NCT04397679?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-08-12. Estimated completion is 2024-05-14.
What interventions are being tested in trial NCT04397679?
The interventions under investigation include: Temozolomide (DRUG), Intensity-Modulated Radiation Therapy (IMRT) (RADIATION), 3-Dimensional Conformal Radiation Therapy (RADIATION), Chloroquine (DRUG), Tumor Treating Fields Therapy (TTF) (PROCEDURE).
Who is sponsoring clinical trial NCT04397679?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.